In this paper, the Nobile lab discovered that four FDA approved drugs could be repurposed for use against biofilms formed by the common human fungal pathogen Candida albicans. This is an exciting finding since currently there are no known drugs available that specifically target biofilms. This work suggests that these drug classes may be useful for treating C. albicans biofilm infections in the clinic.
